GO:1904465 negative regulation of matrix metallopeptidase secretion: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904465 describes any process that stops, prevents, or reduces the frequency, rate, or extent of matrix metallopeptidase (MMP) secretion [1,2,5].
• MMP secretion is a key step in extracellular matrix remodeling, and its negative regulation is critical to prevent excessive tissue degradation in diseases such as diabetic retinopathy and cancer [2,5,8].
• Sirt1 is a well-documented negative regulator of MMP-9 secretion in diabetic retinopathy and skin tissue, acting at least partly through transcriptional repression [2,5].
• Tetraspanin-6 (TSPAN6) negatively regulates exosome production, a process that can overlap with MMP secretion pathways.
• RECK and TIMPs are endogenous inhibitors that can block MMP activity and secretion, influencing angiogenesis and tumor cell adhesion [6,8].
• Studying GO:1904465 requires integrated approaches including CRISPR knockout, live-cell imaging of vesicle trafficking, and proteomic analysis of secreted MMPs [7,8].
Description
Matrix metallopeptidases (MMPs) are a family of zinc-dependent endopeptidases that are secreted or membrane-anchored and collectively capable of degrading essentially all components of the extracellular matrix. Because uncontrolled MMP secretion drives tissue destruction, inflammation, and tumor invasion, cells have evolved dedicated mechanisms to negatively regulate this process. The Gene Ontology term GO:1904465, negative regulation of matrix metallopeptidase secretion, captures any process that stops, prevents, or reduces the frequency, rate, or extent of MMP secretion [1,2,5]. This regulation is essential for maintaining tissue homeostasis and is frequently dysregulated in human disease [2,5,8]. Research into GO:1904465 has revealed multiple layers of control, including transcriptional repression of MMP genes, inhibition of vesicle trafficking, and extracellular sequestration by endogenous inhibitors such as TIMPs and RECK [6,8]. For example, Sirt1 negatively regulates MMP-9 secretion in diabetic retinopathy and skin tissue, highlighting a conserved role for sirtuins in this process [2,5]. Tetraspanin-6 (TSPAN6) has been shown to negatively regulate exosome production, a pathway that intersects with MMP secretion. Understanding these mechanisms is critical for developing therapies that target MMP-driven pathologies without broadly inhibiting beneficial MMP functions. This article provides a comprehensive overview of GO:1904465, integrating authoritative Gene Ontology annotations with real PubMed literature. We cover the molecular players, regulatory mechanisms, disease relevance, and state-of-the-art research methods, including CRISPR-based models and bioinformatics. The content is designed for researchers seeking to interrogate this process and for AI-driven knowledge retrieval systems.
negative regulation of matrix metallopeptidase secretion At A Glance
| GO ID | GO:1904465 |
|---|---|
| GO term | negative regulation of matrix metallopeptidase secretion |
| Ontology | biological_process |
| Synonym | down regulation of MMP secretion; inhibition of matrix metallopeptidase secretion; negative regulation of matrix metalloproteinase secretion |
| Major function | Limits the extracellular release of MMPs, thereby controlling extracellular matrix remodeling and tissue integrity [2,5,8] |
| Key regulators | Sirt1, TSPAN6, RECK, TIMPs [1,2,5,6,8] |
| Disease relevance | Diabetic retinopathy, cancer invasion and metastasis, angiogenesis [2,5,6,7,8] |
| Research methods | CRISPR knockout, live-cell imaging, proteomics, RNA-seq [7,8] |
What Is GO:1904465?
GO:1904465, negative regulation of matrix metallopeptidase secretion, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of matrix metallopeptidase secretion. In other words, it encompasses all cellular and molecular events that limit the release of MMPs from the cell, whether by blocking vesicle trafficking, promoting intracellular retention, or enhancing degradation of MMPs before secretion [1,2,5].
Why Is negative regulation of matrix metallopeptidase secretion Important in Cell Biology?
Negative regulation of MMP secretion is a fundamental homeostatic mechanism that prevents excessive degradation of the extracellular matrix. Dysregulation of this process contributes to a wide range of pathologies, including diabetic retinopathy, cancer invasion, and inflammatory diseases [2,5,8]. Understanding how cells negatively regulate MMP secretion can reveal new therapeutic targets and biomarkers, and it is essential for interpreting data from genome-wide screens and proteomic studies [7,8].
• Prevents uncontrolled extracellular matrix degradation, which is a hallmark of tumor invasion and metastasis.
• Protects against tissue damage in diabetic retinopathy by reducing MMP-9 secretion.
• Maintains skin integrity by limiting stress-induced MMP-9 secretion.
• Regulates angiogenesis by controlling MMP availability and RECK-mediated inhibition.
• Modulates exosome production, which can carry MMPs and other cargo.
• Influences cell adhesion and migration through TIMP-mediated inhibition.
• Provides a mechanism for fine-tuning MMP activity without affecting intracellular MMP functions [2,5].
• Is a potential target for anti-cancer and anti-inflammatory therapies [7,8].
• Helps explain inter-individual variability in MMP-related diseases [2,5].
• Is critical for interpreting CRISPR screens that target secretory pathways.
What Happens During negative regulation of matrix metallopeptidase secretion?
Transcriptional repression of MMP genes
In simple terms: The cell reduces the production of MMP proteins by turning down the genes that encode them.
One of the primary mechanisms to negatively regulate MMP secretion is to reduce MMP gene transcription. Sirt1, a NAD+-dependent deacetylase, has been shown to negatively regulate MMP-9 expression and secretion in diabetic retinopathy and skin tissue [2,5]. This transcriptional control limits the pool of MMPs available for secretion. Other transcription factors and epigenetic modifiers may also contribute, but Sirt1 is a well-documented example [2,5].
Inhibition of vesicle trafficking and exosome production
In simple terms: The cell blocks the packaging and transport of MMPs to the cell surface.
MMPs are secreted via vesicular trafficking pathways, including exosomes. Tetraspanin-6 (TSPAN6) negatively regulates exosome production, which can indirectly limit the secretion of exosome-associated MMPs. Additionally, Coronin 1C promotes MT1-MMP traffic and invadopodia function, suggesting that negative regulation of such trafficking proteins could reduce MMP secretion. The precise molecular machinery that negatively regulates MMP vesicle trafficking is an active area of research.
Extracellular sequestration and inhibition by TIMPs and RECK
In simple terms: Even if MMPs are secreted, they can be immediately blocked by inhibitors outside the cell.
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous proteins that bind to active MMPs and inhibit their proteolytic activity. RECK (reversion-inducing cysteine-rich protein with Kazal motifs) is a membrane-anchored inhibitor of MMPs that plays a key role in angiogenesis. While TIMPs and RECK primarily inhibit MMP activity rather than secretion per se, they contribute to the overall negative regulation of MMP function and can influence secretion through feedback mechanisms [6,8].
Intracellular retention and degradation
In simple terms: The cell keeps MMPs inside and destroys them before they can be released.
Some MMPs can be retained intracellularly or targeted for degradation. For example, Sirt1-mediated deacetylation may promote the degradation of MMP-9 or its retention in the endoplasmic reticulum [2,5]. However, the exact mechanisms of intracellular retention and degradation in the context of GO:1904465 require further investigation. Studies on MMP trafficking have shown that MT1-MMP can be internalized and recycled, suggesting that negative regulation of secretion could involve redirecting MMPs to lysosomes.
Key Genes Involved in GO:1904465 negative regulation of matrix metallopeptidase secretion
The following genes and proteins have been experimentally implicated in the negative regulation of MMP secretion or related processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SIRT1 | NAD+-dependent deacetylase; represses MMP-9 transcription and secretion | Validated in diabetic retinopathy and skin models [2,5] |
| TSPAN6 | Tetraspanin; negatively regulates exosome production | Links exosome biology to MMP secretion |
| RECK | Membrane-anchored MMP inhibitor; regulates angiogenesis | Modulates MMP activity and secretion in cancer |
| TIMP1 | Endogenous inhibitor of MMPs | Broad-spectrum MMP inhibition; affects cell adhesion |
| TIMP2 | Endogenous inhibitor of MMPs | Inhibits MT1-MMP and other MMPs |
| TIMP3 | Endogenous inhibitor of MMPs | Involved in ECM homeostasis and cancer |
| TIMP4 | Endogenous inhibitor of MMPs | Expressed in heart and brain; regulates MMP activity |
| MMP9 | Gelatinase B; secreted MMP | Target of negative regulation by Sirt1 [2,5] |
| MMP2 | Gelatinase A; secreted MMP | Regulated by TIMPs and RECK [6,8] |
| MMP14 | MT1-MMP; membrane-type MMP | Trafficking regulated by Coronin 1C |
| CORO1C | Coronin 1C; regulates MT1-MMP traffic and invadopodia | Promotes cancer invasiveness; potential negative regulator when inhibited |
| CD63 | Tetraspanin; exosome marker | May influence MMP secretion via exosomes |
| CD9 | Tetraspanin; exosome marker | Associated with exosome-mediated MMP secretion |
| SDC1 | Syndecan-1; proteoglycan | Can modulate MMP secretion and activity |
| ITGB1 | Integrin beta-1 | Influences MMP secretion through cell adhesion signaling |
| NFKB1 | Transcription factor | Regulates MMP gene expression; potential negative regulator via feedback |
| SP1 | Transcription factor | Regulates MMP gene expression; context-dependent |
How Is negative regulation of matrix metallopeptidase secretion Regulated?
The negative regulation of MMP secretion is controlled at multiple levels. Transcriptional repression by Sirt1 is a key mechanism, as shown in diabetic retinopathy and skin tissue [2,5]. Post-transcriptional mechanisms, including microRNAs and RNA-binding proteins, may also play a role, though specific examples in the context of GO:1904465 are limited. Vesicle trafficking pathways, such as those involving tetraspanins and coronins, can be regulated by signaling cascades that respond to extracellular cues [1,7]. Additionally, TIMPs and RECK provide extracellular feedback inhibition that can indirectly reduce MMP secretion by preventing MMP-mediated activation of signaling pathways that promote secretion [6,8]. The interplay between these layers ensures tight control of MMP release.
negative regulation of matrix metallopeptidase secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SIRT1 | Diabetic retinopathy; MMP-9 secretion | Sirt1 knockout mice; retinal endothelial cells |
| SIRT1 | Stress-induced skin inflammation | Sirt1 knockout mice; keratinocytes |
| RECK | Angiogenesis; cancer | Reck knockout mice; endothelial cells |
| CORO1C | Triple-negative breast cancer invasiveness | CORO1C knockout breast cancer cell lines |
| TIMP3 | Cancer; ECM homeostasis | TIMP3 overexpression in tumor cells |
Diabetic retinopathy
In diabetic retinopathy, hyperglycemia-induced oxidative stress leads to increased MMP-9 secretion, which contributes to retinal capillary degeneration. Sirt1 acts as a negative regulator of MMP-9, and its downregulation exacerbates MMP-9 secretion and disease progression. Targeting Sirt1 or its downstream pathways could restore negative regulation of MMP-9 secretion and protect against diabetic retinopathy.
Cancer invasion and metastasis
MMP secretion is a hallmark of cancer invasion and metastasis. Negative regulators such as RECK and TIMPs are often downregulated in tumors, leading to excessive MMP activity and ECM degradation [6,8]. Coronin 1C promotes MT1-MMP trafficking and invadopodia function, and its inhibition could enhance negative regulation of MMP secretion and reduce invasiveness. Understanding these mechanisms is critical for developing anti-metastatic therapies [7,8].
Inflammatory skin diseases
Stress-induced MMP-9 secretion in skin tissue contributes to inflammation and ECM damage. Sirt1 negatively regulates stress-induced MMP-9, and its activation may be protective in skin inflammatory conditions. This highlights the therapeutic potential of enhancing negative regulation of MMP secretion in dermatological diseases.
Angiogenesis and vascular disease
RECK is a key negative regulator of angiogenesis through its inhibition of MMPs. Loss of RECK leads to increased MMP secretion and activity, promoting pathological angiogenesis. Modulating RECK or its upstream regulators could provide a strategy to control angiogenesis in cancer and vascular diseases.
From negative regulation of matrix metallopeptidase secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Sirt1 negatively regulate MMP-9 secretion in retinal cells? | SIRT1 knockout (KO) in human retinal endothelial cells |
| Does TSPAN6 regulate exosome-associated MMP secretion? | TSPAN6 KO in HEK293T or cancer cells |
| Does RECK inhibit MMP secretion in angiogenesis? | RECK KO in endothelial cells |
| Does Coronin 1C promote MT1-MMP secretion? | CORO1C KO in triple-negative breast cancer cells |
| Can point mutations in SIRT1 alter its ability to repress MMP-9? | SIRT1 point-mutation knock-in in cell lines |
| Does overexpression of TIMP3 reduce MMP secretion? | TIMP3 overexpression in cancer cell lines |
How to Study the negative regulation of matrix metallopeptidase secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for MMP secretion | Identify novel negative regulators |
| Live-cell imaging | Vesicle trafficking and secretion dynamics | Track MMP-9-GFP in real time |
| Proteomics (mass spectrometry) | Secreted MMP levels | Quantify secretome changes |
| RNA-seq | MMP gene transcription | Determine transcriptional regulation |
| Western blot | Intracellular and secreted MMP protein | Validate KO/overexpression effects [2,5] |
| Zymography | MMP enzymatic activity | Measure gelatinase activity in conditioned media |
| Exosome isolation | Exosome-associated MMPs | Study TSPAN6-mediated regulation |
| Immunofluorescence | Subcellular localization of MMPs | Assess intracellular retention |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes whose loss increases or decreases MMP secretion. For example, knocking out candidate negative regulators such as SIRT1 or TSPAN6 followed by measuring secreted MMP-9 or MMP-2 levels can validate their roles [1,2]. These screens are powerful for discovering novel components of GO:1904465.
Live-cell imaging of vesicle trafficking
Fluorescently tagged MMPs (e.g., MMP-9-GFP) can be used to track vesicle trafficking and secretion in real time. This approach can reveal whether negative regulators block vesicle fusion with the plasma membrane or redirect MMPs to lysosomes. Co-imaging with exosome markers such as CD63 can distinguish exosomal from non-exosomal secretion.
Proteomic analysis of secreted MMPs
Conditioned media from cells with manipulated candidate genes can be analyzed by mass spectrometry to quantify secreted MMPs. This unbiased approach can identify changes in the secretome and validate negative regulation. Combining with SILAC or TMT labeling allows quantitative comparisons.
Transcriptional profiling (RNA-seq)
RNA-seq can determine whether negative regulation occurs at the transcriptional level. For example, Sirt1 knockout may increase MMP-9 mRNA levels, indicating transcriptional repression [2,5]. This method is complementary to secretion assays and helps pinpoint the regulatory layer.
How CRISPR Can Be Used to Study GO:1904465 negative regulation of matrix metallopeptidase secretion
Knockout
CRISPR knockout of candidate negative regulators such as SIRT1 or TSPAN6 can test whether they are required to limit MMP secretion. For example, SIRT1 knockout in retinal endothelial cells increases MMP-9 secretion, confirming its role. Similarly, TSPAN6 knockout increases exosome production, which may carry MMPs. Knockout models are essential for establishing causality in GO:1904465.
Point Mutation
Point mutations can dissect specific domains or catalytic residues. For SIRT1, a point mutation in its deacetylase domain can abolish its ability to repress MMP-9, linking enzymatic activity to negative regulation. Such models are valuable for understanding structure-function relationships in GO:1904465.
Knock-in
Knock-in of tagged versions of MMPs (e.g., MMP-9-GFP) allows real-time tracking of secretion without altering endogenous regulation. Tagged knock-in of SIRT1 or TSPAN6 can also reveal their localization and interactions [1,7]. These models are ideal for imaging-based studies of GO:1904465.
Overexpression
Overexpression of negative regulators such as TIMP3 or RECK can suppress MMP secretion and reduce invasion in cancer models [6,8]. Overexpression of Sirt1 can protect against MMP-9-mediated damage in diabetic retinopathy. These gain-of-function models complement knockout studies and can identify therapeutic candidates.
How EDITGENE Supports negative regulation of matrix metallopeptidase secretion Research
Researchers studying negative regulation of matrix metallopeptidase secretion-related genes often need to determine whether a candidate gene is causally involved in limiting MMP release, and to dissect the underlying molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of matrix metallopeptidase secretion research.
Frequently Asked Questions About negative regulation of matrix metallopeptidase secretion
What is GO:1904465?
GO:1904465 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of matrix metallopeptidase secretion [1,2,5].
What genes are involved in negative regulation of MMP secretion?
Key genes include SIRT1, TSPAN6, RECK, and TIMPs, which have been shown to negatively regulate MMP secretion or activity [1,2,5,6,8].
How does Sirt1 negatively regulate MMP-9 secretion?
Sirt1 represses MMP-9 transcription and may promote its intracellular retention or degradation, as demonstrated in diabetic retinopathy and skin tissue [2,5].
What is the role of TSPAN6 in MMP secretion?
TSPAN6 negatively regulates exosome production, which can limit the secretion of exosome-associated MMPs.
Which diseases are linked to defective negative regulation of MMP secretion?
Diabetic retinopathy, cancer invasion and metastasis, inflammatory skin diseases, and pathological angiogenesis are linked to impaired negative regulation of MMP secretion [2,5,6,7,8].
How can I study negative regulation of MMP secretion using CRISPR?
CRISPR knockout of candidate regulators (e.g., SIRT1, TSPAN6) followed by measuring secreted MMPs via Western blot, zymography, or proteomics is a standard approach [1,2,8].
What are TIMPs and how do they relate to GO:1904465?
TIMPs are tissue inhibitors of metalloproteinases that bind and inhibit MMP activity; they contribute to the negative regulation of MMP function and can influence secretion through feedback.
What is RECK and its role in MMP regulation?
RECK is a membrane-anchored inhibitor of MMPs that negatively regulates angiogenesis and MMP activity.
Can overexpression of TIMP3 reduce MMP secretion?
Yes, overexpression of TIMP3 has been shown to inhibit MMP activity and reduce invasion in cancer models.
What methods are used to measure MMP secretion?
Common methods include zymography, Western blot of conditioned media, ELISA, and mass spectrometry-based proteomics [2,5,8].
Conclusion
GO:1904465, negative regulation of matrix metallopeptidase secretion, is a critical biological process that safeguards tissue integrity by limiting the release of MMPs. Dysregulation of this process contributes to major human diseases, including diabetic retinopathy, cancer, and inflammatory conditions [2,5,6,7,8]. Key regulators such as Sirt1, TSPAN6, RECK, and TIMPs provide promising targets for therapeutic intervention [1,2,5,6,8]. Advances in CRISPR-based models, live-cell imaging, and proteomics are accelerating our understanding of this process. EDITGENE offers a comprehensive toolkit to interrogate GO:1904465, from knockout and point-mutation models to overexpression and library screening, empowering researchers to uncover new mechanisms and translate them into clinical applications.
References
- 1. Ghossoub R et al.. 2020. Tetraspanin-6 negatively regulates exosome production.. Proc Natl Acad Sci U S A 117(11):5913-5922 PMID: 32108028
- 2. Kowluru RA et al.. 2014. Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy.. Invest Ophthalmol Vis Sci 55(9):5653-60 PMID: 24894401
- 5. Lee JS et al.. 2010. Negative regulation of stress-induced matrix metalloproteinase-9 by Sirt1 in skin tissue.. Exp Dermatol 19(12):1060-6 PMID: 20812964
- 6. Gutiérrez J et al.. 2016. A Hypothesis for the Role of RECK in Angiogenesis.. Curr Vasc Pharmacol 14(1):106-15 PMID: 26463982
- 7. Castagnino A et al.. 2018. Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function.. Oncogene 37(50):6425-6441 PMID: 30065298
- 8. Bourboulia D et al.. 2010. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.. Semin Cancer Biol 20(3):161-8 PMID: 20470890
